Oklo Stock Drops 3.2% Amid Analyst Concerns

Shares of nuclear microreactor firm Oklo fall as Wall Street trims price targets

Apr. 1, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

Shares of Oklo Inc. (NYSE:OKLO), a California-based energy technology company specializing in advanced nuclear microreactors, traded down 3.2% on Wednesday, closing at $47.98 per share. The stock decline came as Wall Street analysts lowered their price targets for the company amid broader market volatility.

Why it matters

Oklo is seen as a promising player in the emerging small modular reactor (SMR) market, which aims to deliver carbon-free nuclear power through compact, factory-built units. The company's stock performance and analyst sentiment are closely watched as indicators of the commercial viability of its Aurora microreactor technology.

The details

Several equity research firms have recently adjusted their price targets for Oklo's stock. Barclays decreased its target from $146 to $82, while UBS Group cut its target from $95 to $60. The analysts cited broader market conditions and uncertainty around the company's timeline for commercializing its reactor design.

  • Oklo's stock closed at $47.98 per share on Wednesday, April 1, 2026.
  • The stock traded as low as $47.92 earlier in the day.

The players

Oklo, Inc.

A California-based energy technology company specializing in the design and development of advanced nuclear microreactors, with a focus on small modular reactor (SMR) technology.

Barclays

A multinational investment bank that decreased its price target for Oklo's stock from $146 to $82.

UBS Group

A global financial services firm that reduced its price target for Oklo's stock from $95 to $60.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain cautious on Oklo's near-term prospects as the company works to commercialize its innovative reactor technology.”

— Barclays Analyst

“While Oklo's long-term potential is promising, current market conditions and regulatory uncertainties warrant a more conservative valuation approach.”

— UBS Analyst

What’s next

Oklo's management team is expected to provide an update on the company's commercialization timeline and regulatory progress during its next quarterly earnings call, scheduled for May 15, 2026.

The takeaway

Oklo's stock decline highlights the challenges facing innovative nuclear technology firms as they navigate a complex regulatory environment and volatile market conditions. The company's ability to execute on its commercialization plans will be crucial in determining the long-term viability of its advanced microreactor technology.